EP Patent

EP4591934A2 — Variants of c-type natriuretic peptide

Assigned to Biomarin Pharmaceutical Inc · Expires 2025-07-30 · 1y expired

What this patent protects

The invention provides a conjugate of a C-type natriuretic peptide (CNP) variant, wherein the amino acid sequence of the CNP variant is LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38), and a polyethylene glycol (PEG) polymer, and its use for the treatment of disorders of bone gr…

USPTO Abstract

The invention provides a conjugate of a C-type natriuretic peptide (CNP) variant, wherein the amino acid sequence of the CNP variant is LQEHPNARKYKGANKKGLSKGCFGLKLDRIGSMSGLGC (CNP-38), and a polyethylene glycol (PEG) polymer, and its use for the treatment of disorders of bone growth such as skeletal dysplasia.

Drugs covered by this patent

Patent Metadata

Patent number
EP4591934A2
Jurisdiction
EP
Classification
—
Expires
2025-07-30
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.